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Epidermal growth factor receptor (EGFR) has been implicated in tumour growth and extension of ovarian cancer. Peritoneal fluid in
ovarian cancer patients contains various growth factors that can promote tumour growth and extension. In order to investigate the
clinical significance of EGFR ligands as activating factors of ovarian cancer, we examined the cell proliferation-promoting activity and
the level of EGFR ligands in peritoneal fluid obtained from 99 patients. Proliferation-promoting activity in peritoneal fluid from 63
ovarian cancer patients (OVCA) was much higher than peritoneal fluid from 18 ovarian cyst patients (OVC) and 18 normal ovary
patients (NO), and the activity was suppressed only by antibodies against EGFR or heparin-binding epidermal growth factor (HB-
EGF). A large difference was observed in the level of EGFR ligands between HB-EGF and TGF-a or amphiregulin. The concentration
of HB-EGF in OVCA significantly increased compared to that in OVC or NO (Po0.01). No significant difference in the concentration
of TGF-a and amphiregulin was found between the OVCA and NO or OVC groups. In peritoneal fluid, HB-EGF is sufficiently
elevated to activate cancer cells even at an early stage of OVCA. These results suggested that HB-EGF in peritoneal fluid might play
a key role in cell survival and in the proliferation of OVCA.
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Ovarian cancer (OVCA) is the most frequent cause of cancer death
among all gynaecologic cancers, and in the last 30 years current
therapies have not improved cure rates (Penson et al, 1998). The
high mortality is caused predominantly by the occult progression
of the tumour into the peritoneal cavity with an initial diagnosis
usually being made at an advanced stage. Tumour growth is
characterised by local extension into the peritoneal cavity
following the circulatory pathway of the peritoneal fluid produced
by peritoneal epithelium and cancer cells. Accumulated evidence
from many studies reveals that ascites from OVCA patients is a
rich source of growth factor activity for OVCA cells, termed
ovarian cancer activating factors (OCAFs) (Mills et al, 1998). The
dissemination of cancer cells activated by OCAFs result in an
exaggerated increase in peritoneal fluid, which in turn leads to
tumour extension of OVCA.
To identify OCAFs of OVCA, various peptide growth factors and
cytokines have been detected in the malignant effusions of OVCA
patients (Westermann et al, 1997). However, the growth-promot-
ing properties of malignant effusions in vivo and in vitro have been
shown to be independent of these peptide growth factors
(Westermann et al, 1997). Recent biochemical analysis has
revealed that one possible OCAF candidate is lysophophatidic
acid (LPA) (Xu et al, 1995; Westermann et al, 1998; Xiao et al,
2001). Lysophophatidic acid is a simple phospholipid with
numerous cellular effects including growth promotion, cell cycle
progression and cytoskeletal organisation (Mills and Moolenaar,
2003). However, LPA may not be the sole mediator present in
ascites because the proliferation of cancer cells was lower than that
induced by ascites from OVCA patients, even at optimal LPA
concentrations (Xu et al, 1995).
Impairment of the epidermal growth factor (EGF) system has
been implicated in the pathogenesis of different types of carci-
nomas (Salomon et al, 1995; Normanno et al, 2003). As described
in the literature (Salomon et al, 1995; Normanno et al, 2003), EGF
receptor (EGFR) overexpression occurs in 35–70% of all primary
OVCAs and the overexpression of ErbB2 is correlated to clinical
outcome. Whereas the frequency of ErbB2 overexpression is low,
the frequencies of ErbB3 and ErbB4 expressions are high in OVCA.
Univariate and multivariate statistical analyses have confirmed
that EGFR overexpression is significantly associated with a high
risk of progression in OVCA patients (Scambia et al, 1992). Seven
ligands have been described for EGFR: EGF, transforming growth
factor-a (TGF-a). heparin-binding-EGF like growth factor (HB-
EGF), amphiregulin (AR), betacellulin, epiregulin, and epigen
(Fischer et al, 2003). All are synthesised as membrane-spanning
precursor molecules that have to be proteolytically processed to
become fully active (Fischer et al, 2003). A relatively high
frequency of TGF-a and AR has been described in ovarian
carcinomas, although staining in tumours varied from weak to
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sstrong (Morishige et al, 1991; D’Antonio et al, 2002). Ovarian
cancer cells are sensitive to diphtheria toxin, indicating the
expression of proHB-EGF (Morimoto et al, 1991). We reported
that HB-EGF is involved in EGFR signal transactivation induced by
LPA in OVCA cell lines, and that the soluble form of HB-EGF is
attributable to tumour growth on xenografted mice using OVCA
cell lines (Miyamoto et al, 2004). On the basis of these results, it is
suggested that EGFR plays a pivotal role in the acceleration and
progression of ovarian caner through EGFR ligands including
TGF-a, HB-EGF, and AR.
The concentration of EGFR ligands was examined to determine
their role as tumour-promoting factors in the peritoneal fluid of
OVCA patients. Peritoneal fluid of OVCA patients was also
examined for proliferation-promoting and cell survival activities
in OVCA cells in the absence or presence of specific inhibitory
antibodies against EGFR and EGFR ligands.
MATERIALS AND METHODS
Patients and peritoneal fluids
All of the 99 patients in this study underwent surgery between 1994
and August 2003 at the Department of Obstetrics and Gynecology,
Kyushu University Hospital. Peritoneal fluids were obtained from
99 women, who gave signed informed consent (Table 1). In all, 18
cases with normal ovaries had surgical treatment due to uterine
myomas or benign gynaecologic disorders. In six cases with
marked ascites and multiple disseminating sites in the peritoneum,
peritoneal fluids were obtained twice, once before chemo-
therapy and once after three courses of chemotherapy, under a
presurgical state. Peritoneal fluid supernatants were collected
immediately after centrifugation (3000g 15min), and stored at
 801C until use.
Reagents
Recombinant human HB-EGF and synthetic LPA were purchased
from R&D Systems Inc. (Minneapolis, MN, USA) and from Avanti
Polar Lipids, Inc. (Alabaster, AL, USA), respectively. [
3H]thymi-
dine (6.7Cimmol
 1) was obtained from New England Nuclear
(Lachine, Quebec, Canada). Mouse anti-human EGF receptor
neutralising antibody and goat anti-human HB-EGF neutralising
antibody was obtained from Upstate Inc. (Lake Placid, NY, USA)
and R&D Systems Inc. (Minneapolis, MN, USA), respectively. Goat
anti-human TGF-a neutralising antibody, mouse anti-human AR
neutralising antibody, mouse anti-human EGF neutralising anti-
body, goat anti-human epiregulin neutralising antibody and goat
anti-human betacellulin neutralising antibody were also purchased
from GT (Minneapolis, MN, USA). The manufacturer’s instruc-
tions detail that at least 5ngml
 1 of EGFR and EGFR ligands (EGF,
TGF-a, HB-EGF, AR, betacellulin and epiregulin) can be neutra-
lized in the use of 10mgml
 1 of these antibodies, respectively.
Polyclonal rabbit anti-EGFR and anti-ErbB-4 antibodies were
obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA)
and Upstate Biotechnology Inc. (Lake Placid, NY, USA), respec-
tively. Peroxidase-conjugated goat anti-rabbit IgG was purchased
from Zymed (San Francisco, CA, USA).
Immunoblot
Cells were rinsed in phosphate-buffered saline (PBS) and then
lysed in RIPA buffer (1% Triton X-100, 1% sodium deoxycholate,
0.1% SDS, 150mM NaCl, 50mM Tris (pH 8.0), 0.2 unistml
 1
aprotinin, 2mgml
 1 leupeptin, 1mgml
 1 pepstatin A, 2mM phenyl-
methylsulphonyl fluoride). In all, 50mg of extracts wsa then subjected
to SDS–polyacrylamide gel electrophoresis (SDS–PAGE) and
immunoblotting analysis (Miyamoto et al, 2004).
Cell proliferation-promoting assay mediated by factors in
peritoneal fluid
SKOV3 cells, derived from OVCA, were maintained in RPMI-1640
(Nacalai Tesque Co. Ltd., Kyoto, Japan) supplemented with 10%
(vv
 1) fetal bovine serum (FBS). To remove extracellular matrix
components, cells were detached with trypsin-EDTA, then allowed
to recover for 30min in RPMI-1640 with 10% FBS. After rinsing
with serum-free medium, cells were incubated with serum-free
medium at 371C for 30min. Cells (1 10
4) were seeded on poly-
lysine-coated dishes, and samples incubated with serum-free
RPMI-1640 at 371C for 1h to assure the complete adherence of
cells to the poly-lysine-coated dishes. To assess cell proliferative
activity, cells were incubated in 200ml of RPMI-1640 plus 90% of
each human peritoneal fluid at 371C for 24h; then WST-1 assay
(Dojin Laboratory, Kumamoto, Japan) was performed according to
the manufacturer’s instructions. Further, to reconfirm the
potential of the DNA polymerisation induced by peritoneal fluids,
[
3H]thymidine incorporation was examined in SKOV 3 cells, using
10% human peritoneal fluid. The cells were treated in the same
manner as the WST-1 assay, and the medium was then replaced
with RPMI-1640 plus 10% of each human peritoneal fluid for an
additional 24h in the absence or presence of inhibitory antibodies
against EGFR, HB-EGF, TGF-a, amphiregulin, epiregulin, betacel-
lulin, and EGF, or with RPMI-1640 plus 10% peritoneal fluid from
patients with a normal ovary (NO) in the absence or presence of
various concentrations of LPA or HB-EGF. Peritoneal fluids from
30 patients with OVCA (five cases at stage Ia, five at Ic-II, 15 at
III–IV, and five of recurrence) were available for the experiment
using inhibitory antibodies. [
3H]thymidine (1mCiwell
 1) was then
added to the cell culture. After 4h of labelling with [
3H]thymidine,
cells were washed with PBS, lysed with NaOH and treated with
TCA. After adding scintillation fluid, [
3H]thymidine uptake was
measured in a b-scintillation counter. Each experiment was
conducted in triplicate. The mean value was considered as the
representative value for each experiment. The WST-1 assay and the
[
3H]thymidine incorporation were also examined in other OVCA
cell lines including RMG-1 and OVMG1 cells in 10 cases with a NO
and in 20 cases with OVCA.
Inhibition of cell apoptotic assay mediated by factors in
peritoneal fluid
The OVCA cell lines (1 10
5) of SKOV3, RMG-1, and OVMG1
were treated in the same manner as in the WST-1 assay. Thereafter,
this medium was replaced with the RPMI-1640 plus 10% of each
human peritoneal fluid for an additional 24h in the absence or
presence of inhibitory antibodies against HB-EGF. Cells were
harvested, pooled, and then fixed with 4% paraformaldehyde and
70% ethanol. After further washing in PBS, cells were incubated
with TdT reaction reagent for 1h at 371C, according to the
manufacturer’s recommended protocol (MEBSTAIN Apoptosis Kit
Table 1 Clinical data for patients
Histological types
Variable
No. of
patients
Age (years)
(mean7s.d.) Serous Others
Normal ovary 18 55.5717.8
Ovarian cyst 18 54.6719.7 10 8
Ovarian cancer, stage Ia 10 57.2714.3 7 3
Ovarian cancer, stage Ic–II 13 55.8710.6 8 5
Ovarian cancer, stage III–IV 30 59.3716.2 22 8
Ovarian cancer, recurrence 10 58.2711.2 7 3
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sDirect, MBL, Co., Ltd, Japan). TUNEL-positive cells were
quantified as apoptotic cells by flow cytometric analysis (Becton
Dickinson, FACScan, 01-20126-xx, USA).
Binding assay for HB-EGF
The binding of
125I-diphtheria toxin (DT) to HB-EGF was
measured as described previously (Iwamoto et al, 1994). Briefly,
1ml of peritoneal fluid was incubated with heparin-sepharose
CL-6B for 5h at 41C. The gel was washed three times with PBS and
incubated with
125I-DT in the presence or absence of excess
unlabelled DT for 12h at 41C. It was then washed three times with
PBS and three times with high-salt PBS. The radioactivity bound to
the gel was counted with a gamma counter, and the specific
binding of
125I-DT to the HB-EGF molecule was calculated by
subtracting the radioactivity of the sample in the presence of
unlabelled DT from that of the sample in the absence of unlabelled
DT. The amount of HB-EGF was estimated by the standard curve
obtained using recombinant human HB-EGF. All experiments were
conducted in triplicate and the mean HB-EGF value was regarded
as the representative value of HB-EGF in each case.
Immunoassay for human TGF-a and AR
Concentrations of TGF-a and AR in peritoneal fluid were
determined with a commercially available ELISA (Quantikine
Kit, R&D Systems Inc. and ELISA Development Kit, GT,
Minneapolis, MN, USA) in accordance with the manufacturer’s
instructions. Samples were analysed in triplicate. Levels of TGF-a
and AR were calculated from the linear areas of the standard
curves obtained using Multiskan MS, version 8.0 (Labsystems,
Helsinki, Finland), respectively. The mean value was used as the
representative value. The lower limits for detection of TGF-a and
AR were 5 and 10pgml
 1, respectively. When the amount was less
than the detection limit, the TGF-a or AR value was recorded as 5
or 10pgml
 1, respectively.
Statistical analysis
The statistical significance was assessed using the Mann–Whitney
test and a P-value less than 0.05 was considered statistically
significant.
RESULTS
To investigate the expression of EGFR and ErbB-4 in the OVCA
cell lines of SKOV3, RMG-1, and OVMG1, each protein expression
was examined using immunoblotting analysis. The expression of
EGFR in RMG-1 cells increased remarkably compared to those in
SKOV3 or OVMG1 cells. There was little difference in the
expression of ErbB4 among these three lines of OVCA cells
(Figure 1A).
To assess the cell proliferative property mediated by factors in
peritoneal fluid, cell proliferation of SKOV3 cells was examined
using the WST-1 assay after incubation with peritoneal fluid.
WST-1 assay demonstrated that the value in patients with OVCA
significantly increased compared to that in patients with a NO or
ovarian cyst (OVC) (Figure 1B and Table 2). To address whether
peritoneal fluid from OVCA patients actually stimulates cancer cell
proliferation, the proliferation of SKOV3 cells was examined by
[
3H]thymidine incorporation into DNA. In the absence of the
patient’s peritoneal fluid, SKOV3 cells showed [
3H]thymidine
incorporation at a minimum value (580071200cpm). Addition of
peritoneal fluid resulted in increased DNA synthesis in all cases,
but peritoneal fluid from OVCA patients enhanced DNA synthesis
much highly than that from NO and OVC (each Po0.01)
(Figure 1C and Table 2). In the WST-1 assay, the absorbances of
the 10 cases with a NO and the 20 cases with OVCA were
0.3170.12 and 0.6270.23 (mean7standard deviation) (RMG-1
cells), and 0.3070.13 and 0.6970.23 (OVMG1 cells), respectively.
In RMG-1 and OVMG1 cells, the proliferative activity in peritoneal
fluid of OVCA patients was significantly enhanced, compared with
that in NO (both Po0.01). In [
3H]thymidine incorporation, the
values in the 10 cases with a NO and the 20 cases with OVCA
were 582371066c.p.m. (count per minute) and 924171553
c.p.m (mean7standard deviation) (RMG-1 cells), and 69037
1134c.p.m. and 1257271951c.p.m. (OVMG1 cells), respectively.
In RMG-1 and OVMG1 cells, the DNA polymerisation property
mediated by peritoneal fluid in OVCA was also significantly
elevated, compared with that in NO (both Po0.01). These results
indicate that peritoneal fluid in patients with OVCA possesses a
significant cell proliferative property.
To examine which EGFR ligands contribute to SKOV3 cell
proliferation in a patient’s peritoneal fluid, the effects of peritoneal
fluid on SKOV3 cell DNA synthesis were measured in the absence
or presence of an inhibitory antibody against EGFR or each EGFR
ligand. [
3H]thymidine incorporation was significantly reduced in
the presence of anti-EGFR or anti-HB-EGF neutralising antibody,
while neutralising antibodies against TGF-a, AR, epiregulin,
betacellulin, and EGF had no effect on [
3H]thymidine incorpo-
ration in SKOV3 cells (Figure 1D). The contribution of epigen
was not determined, as no antibodies against epigen are available.
In the presence of inhibitory antibodies against HB-EGF or EGFR,
the values of [
3H]thymidine incorporation were 730171093 and
730871120c.p.m (RMG-1 cells), and 951371510 and 91607
1296c.p.m. (OVMG1 cells), respectively. [
3H]thymidine incor-
poration was also significantly reduced in the presence of
anti-EGFR or anti-HB-EGF neutralising antibodies using RMG-1
or OVMG1 cells.
To evaluate the role of HB-EGF in cell survival in peritoneal
fluid, apoptotic cells were analysed using the FACScan after
staining cells by TUNEL methods in 10% human peritoneal
fluid with an absence or presence of an inhibitory antibody
against HB-EGF. Significant apoptotic cells in RMG-1 and OVMG1
cells were not observed even under serum-free conditions. In
SKOV3 cells, 25.171.4% (mean7standard deviation) were de-
tected as TUNEL-positive under serum-free conditions
(Figure 2C). In a patient with a NO, there was no difference in
the percentage of apoptotic cells between an absence or presence of
peritoneal fluid, or between an absence or presence of the
inhibitory antibody plus peritoneal fluid (Figure 2A). In a patient
with OVCA, the percentage of apoptotic cells incubated
with peritoneal fluid markedly decreased, compared to that
incubated without peritoneal fluid (Figure 2B). As well, peritoneal
fluid plus the inhibitory antibody against HB-EGF blocked
any decrease of apoptotic cells (Figure 2B and C). In the 10
cases with a NO or the 20 cases with OVCA, the percentages
of apoptotic cells were 24.674.6 or 3.372.2%, respectively,
after incubation with peritoneal fluid (Figure 2C). In peritoneal
fluid from OVCA patients in the presence of the inhibi-
tory antibody against HB-EGF, the percentage of apoptotic
cells significantly increased at 18.275.2%, compared with
that in the absence of the inhibitory antibody (Po0.01)
(Figure 2C). These results suggest that HB-EGF in the peritoneal
fluid of OVCA patients may contribute to cell survival in
OVCA cells.
The present study suggests that HB-EGF levels may increase in
peritoneal fluid from OVCA patients, and that HB-EGF is one of
the factors in peritoneal fluid from OVCA patients that promotes
tumour growth. Thus, HB-EGF, in addition to LPA, should
be included as a member of OCAFs. To compare HB-EGF with
LPA for proliferation-promoting activity, SKOV3 cells were
cultured either with HB-EGF or LPA in a culture medium
containing peritoneal fluid of NO patients. Although the con-
centration of LPA in the peritoneal fluid of OVCA patients
HB-EGF promotes tumour growth and extension
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sis reportedly from 10 to 20mM (Xu et al, 1995; Westermann
et al, 1998; Xiao et al, 2001), LPA (0–50mM) did not show any
growth-promoting effect in the present cell system (Figure 3A). In
contrast, HB-EGF enhanced SKOV3 cell proliferation in a dose-
dependent manner (Figure 3B), even at concentrations of 1–
10ngml
 1, which are comparable to the levels of HB-EGF in
peritoneal fluid of OVCA patients. These results indicate that HB-
EGF induced significant cell proliferation, even in the presence of a
concentration of 1ngml
 1.
To gain an insight into the role of EGFR ligands in peritoneal
fluid of OVCA patients, the concentrations of HB-EGF, TGF-a, and
AR were determined in the peritoneal fluid of patients with a NO ,
OVC, and OVCA. Heparin-binding epidermal growth factor levels
were significantly enhanced in all stages in OVCA patients
compared with levels in NO and OVC patients (Po0.01)
(Figure 4A and Table 2). Transforming growth factor–a levels
were quite low (less than 40pgml
 1) in all cases, and 46 out of 99
cases (four cases of NO, six cases of OVC, 30 cases of OVCA, and
six cases of recurrence of OVCA) showed levels lower than the
detection limit (5pgml
 1). Amphiregulin levels were scattered
among the cases, but were less than 1000pgml
 1 except in three
OVCA cases. No significant differences were found in TGF-a and
AR levels among the patients with NO, OVC, and OVCA (Figure
4B, C and Table 2). In addition to the significant increase of HB-
EGF levels in OVCA patients, the concentration of HB-EGF in the
peritoneal fluid of OVCA patients was much higher than those of
TGF-a and AR (Figure 4), suggesting that HB-EGF is a major EGF
family ligand, and is involved in tumour growth and OVCA
extension.
To elucidate the relationship between EGFR ligands and clinical
outcome, the amounts of EGFR ligands in peritoneal fluid were
compared between before and after chemotherapy. Of the six cases
examined, three cases showed a good response to neo-adjuvant
chemotherapy and a marked reduction in tumour size and
peritoneal fluid. In these cases, computed tomography indicated
the disappearance of the tumour in the abdomen with six
courses of chemotherapy. The other three cases did not respond
to neo-adjuvant chemotherapy and there was no marked effect on
tumour growth or the volume of peritoneal fluid. The levels of
HB-EGF were dramatically reduced in the former cases, but were
slightly increased in the latter ones (Figure 5A). No significant
changes in TGF-a and AR were observed between pre- and
post-chemotherapy (Figure 5B and C). These results suggest that
HB-EGF levels in peritoneal fluid might reflect the response to
chemotherapy.
DISCUSSION
In this study, we have shown the following: (1) HB-EGF levels in
peritoneal fluid were elevated at all stages and at recurrence, and
levels of HB-EGF were sufficient to proliferate and to allow survival
of OVCA cells, whereas the levels of the other five EGFR ligands in
peritoneal fluid had little effect on the proliferation of OVCA cells.
(2) Cell proliferation of OVCA cells was stimulated by the addition
of HB-EGF, but not LPA, in in vitro study. (3) Changes in the
amount of HB-EGF were reflected by therapeutic efficacy in OVCA
patients. Taken together, the present study suggests that HB-EGF
plays a pivotal role in tumour growth and extension of OVCA. In
this study, however, cell proliferative activities in SKOV3, RMG-1,
or OVMG1 cells, which were mediated by peritoneal fluid from
OVCA patients, were not always dependent on the expression of
EGFR or ErbB-4. It remains open to debate how EGFR or ErbB-4 is
involved in the cell proliferation mediated by peritoneal fluid in
OVCA patients.
Among the members of EGF family growth factors, HB-EGF, AR,
and betacellulin have heparin-binding properties (Raab and
Klagsbrun, 1997; Iwamoto and Mekada, 2000; Strachan et al,
2001). Heparin-binding epidermal growth factor is also known to
have a broad spectrum of biological activities including mitogenic
activity, chemotaxis, adhesion, and angiogenesis (Raab and
Klagsbrun, 1997; Iwamoto and Mekada, 2000). Increasing evidence
indicates that HB-EGF is involved in various pathophysiological
disorders. Recently, it has been shown that EGFR is transactivated
by a variety of stimuli through the ectodomain shedding of EGFR
ligands, and that HB-EGF plays a central role in this process
(Prenzel et al, 1999). Lysophophatidic acid and other ligands for G
protein coupled receptors (GPCR) also transactivate EGFR through
ectodomain shedding of HB-EGF or AR (Prenzel et al, 1999; Umata
et al, 2001; Gschwind et al, 2003). In OVCA, LPA has been
Figure 1 Cell proliferation activity mediated by peritoneal fluid in patients with a normal ovary (NO), an ovarian cyst (OVC), or ovarian cancer (OVCA).
(A) Expression of EGFR and ErbB-4 protein in SKOV3, RMG-1, and OVMG1 cells. Lanes 1 and 4: SKOV3 cells. Lanes 2 and 5: RMG-1 cells. Lanes 3 and 6:
OVMG1 cells. (B) The value of absorbance in the WST-1 assay in SKOV3 cells incubated with patients’ peritoneal fluid from an NO, an OVC, and an OVCA
at clinical stages Ia, Ic-II, III–IV, and recurrence. Closed circles indicate the value of absorbance in each patient. Horizontal lines indicate mean values. The P-
value represents comparison with the levels of patients with an NO and an OVC. (C) The [
3H]thymidine incorporation in SKOV3 cells incubated with
patients’ peritoneal fluid of a NO, an OVC, and an OVCA at clinical stages Ia, Ic-II, III–IV, and recurrence. Closed circles indicate the value of [
3H]thymidine
incorporation in each patient. Horizontal lines indicate mean values. The P-value represents comparison with the levels of patients with a normal ovary and
an ovarian cyst. (D) Alterations in the [
3H]thymidine incorporation of an ovarian cancer patient’s peritoneal fluid by anti-EGFR ligand antibodies or an anti-
EGFR antibody. A bar indicates the mean value and standard errors. The P-value represents comparison with the levels of patients in the absence of
inhibitory antibodies.
Table 2 Concentrations of HB-EGF, TGF-a, and amphiregulin, and cell proliferation properties in peritoneal fluid
Concentration of EGF ligands (pgml
 1, mean7s.d.) Proliferation-promoting activities (mean7s.d.)
Variable HB-EGF TGF-a Amphiregulin
[
3H]Thymidine
incorporation (c.p.m.) WST-1 assay (abs.)
Normal ovary (N¼18) 4837495 11.12713.01 987236 921675777 0.1270.11
Ovarian cyst (N¼18) 6537616 7.3773.67 1867322 899075381 0.2670.18
Ovarian cancer, stage Ia (N¼10) 309072286* 7.4574.01 2147183 2174778678** 0.7170.29***
Ovarian cancer, stage Ic–II (N¼13) 213271394* 8.3377.47 2037220 1865474988** 0.7670.33***
Ovarian cancer, stage III–IV (N¼30) 205371204* 5.1470.62 2257755 24556710152** 0.8670.66***
Ovarian cancer, Recurrence (N¼10) 254471098* 2.0175.12 2127175 2103579755** 0.7870.28***
*Po0.01 for comparison of HB-EGF level vs normal ovary. **Po0.01 for comparison of c.p.m. count vs normal ovary. ***Po0.01 for comparison of absorbance vs normal ovary.
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sidentified as a candidate for an OCAF (Xu et al, 1995; Westermann
et al, 1998; Xiao et al, 2001). In our study, LPA did not stimulate
SKOV3 cell proliferation in the presence of peritoneal fluid of NO
patients; however, the effect of LPA might be dependent on the cell
system. In contrast, HB-EGF stimulated SKOV3 cell proliferation
in the same culture conditions. Therefore, it is likely that LPA is an
OCAF, but it stimulates OVCA cell proliferation by inducing the
ectodomain shedding of HB-EGF, rather than directly acting by
itself on cancer cells.
In OVCA, LPA regulates the production of LPA itself
through the activation of phospholipase D and phospholipase A2
(Eder et al, 2000). Similarly, HB-EGF induces HB-EGF gene
expression itself by activating mitogenic properties (Tan et al,
1994). In addition, LPA and HB-EGF appear to influence
their reciprocal production. Lysophophatidic acid can enhance
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Figure 3 Mitogenic activity of LPA (A) and HB-EGF (B) in the presence
of peritoneal fluid. Each point indicates the mean and standard deviation of
[
3H]thymidine incorporation. The P-value represents comparison with the
levels of [
3H]thymidine incorporation incubated in the medium containing
peritoneal fluid of a patient with a normal ovary.
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Figure 2 Cell survival activity mediated by peritoneal fluid in patients
with a normal ovary or ovarian cancer. Flow cytometric analysis for
apoptotic cells in SKOV3 cells after incubation with peritoneal fluid of a
normal ovary (A) and ovarian cancer (B). Control (a: black line). Under
serum-free condition (b: green line). Incubation with 10% peritoneal fluid in
the absence (c: red line) or presence (d: blue line) of an inhibitory antibody
against HB-EGF. Each percentage indicates the ratio of apoptotic cells in
SKOV3 cells. (C) Alteration in the percentage of apoptotic cells after
incubation with the peritoneal fluid from a normal ovary or ovarian cancer.
A bar indicates the mean value and standard errors. The P-value represents
comparison with the levels of patients with a normal ovary.
HB-EGF promotes tumour growth and extension
H Yagi et al
1742
British Journal of Cancer (2005) 92(9), 1737–1745 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sthe gene expression of HB-EGF (Goetzl et al, 1999), as well as
induce the ectodomain shedding of HB-EGF (Prenzel et al,
1999; Umata et al, 2001). Heparin-binding epidermal growth
factor activates EGFR, and the activated EGFR enhances the
activity of phospholipase D, which in turn causes the production
of LPA (Yeo and Exton, 1995). Considering this evidence as a
basis, HB-EGF and LPA might collaborate in inducing cell
proliferation and in amplifying their own production. In
this study, we showed that HB-EGF is elevated in the ascitic
fluid of OVCA patients even at an early stage. Lysophophatidic
acid may contribute to the production of HB-EGF, especially in an
early phase of OVCA.
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Figure 4 Distribution of HB-EGF (A), TGF-a (B), and AR (C) concentration in peritoneal fluid among patients with a normal ovary (NO), an ovarian cyst
(OVC), or ovarian cancer (OVCA) at clinical stages Ia, Ic-II, III–IV, and recurrence. Closed circles indicate the value of EGFR ligand concentration in each
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generated mainly from cancer cells and peritoneal mesothelial
cells, which have the same origin as coelomic epithelium of the
NO. Our study showed that HB-EGF levels were already elevated
even in the ascitic fluid of patients with stage Ia OVCA, whereas
OVCA cells are enclosed within the cyst wall. This suggests that
HB-EGF is not secreted from cancer tissues in an early stage. In
peritoneal mesothelial cells, HB-EGF is constitutively expressed
and produced by cytokine stimulation (Jayne et al, 2000).
Therefore, it is possible to speculate that during early OVCA,
mainly peritoneal mesothelial cells produce HB-EGF in the
peritoneal fluid by stimulation of a variety of cytokines or by
LPA. In advanced stages of OVCA, however, the HB-EGF levels in
the peritoneal fluid appear to be correlated with the tumour state
in the peritoneal cavity, as HB-EGF levels of patients’ fluids were
largely reduced after chemotherapy in chemotherapy-responding
cases. Therefore, in advanced OVCA, both cancer and peritoneal
mesothelial cells might produce HB-EGF.
These results are the first demonstration of HB-EGF as an
OCAF. Heparin-binding epidermal growth factor is known to
enhance cell motility as well as cell proliferation. Therefore,
elevated HB-EGF in peritoneal fluid may contribute to not only
survival and proliferation of cancer cells, but also to their
dissemination into the peritoneal cavity. It is easier to measure
HB-EGF levels in peritoneal fluid compared with LPA, suggesting
that HB-EGF is a promising bioactive marker of OVCA. For
therapy, relevant LPA antagonists have yet to be developed, while
Iressa, a specific EGFR tyrosine-kinase inhibitor, is not effective in
OVCA (Baselga et al, 2002). Thus, the development of therapeutic
tools against HB-EGF would allow the exploration of novel
targeting therapies for OVCA.
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